Fibronectin is a stress responsive gene regulated by HSF1 in response to geldanamycin
- Dhanani, Karim C H, Samson, William J, Edkins, Adrienne L
- Authors: Dhanani, Karim C H , Samson, William J , Edkins, Adrienne L
- Date: 2017
- Language: English
- Type: article , text
- Identifier: http://hdl.handle.net/10962/59931 , vital:27711 , https://doi:10.1038/s41598-017-18061-y
- Description: Fibronectin is an extracellular matrix glycoprotein with key roles in cell adhesion and migration. Hsp90 binds directly to fibronectin and Hsp90 depletion regulates fibronectin matrix stability. Where inhibition of Hsp90 with a C-terminal inhibitor, novobiocin, reduced the fibronectin matrix, treatment with an N-terminal inhibitor, geldanamycin, increased fibronectin levels. Geldanamycin treatment induced a stress response and a strong dose and time dependent increase in fibronectin mRNA via activation of the fibronectin promoter. Three putative heat shock elements (HSEs) were identified in the fibronectin promoter. Loss of two of these HSEs reduced both basal and geldanamycin-induced promoter activity, as did inhibition of the stress-responsive transcription factor HSF1. Binding of HSF1 to one of the putative HSE was confirmed by ChIP under basal conditions, and occupancy shown to increase with geldanamycin treatment. These data support the hypothesis that fibronectin is stress-responsive and a functional HSF1 target gene. COLA42 and LAMB3 mRNA levels were also increased with geldanamycin indicating that regulation of extracellular matrix (ECM) genes by HSF1 may be a wider phenomenon. Taken together, these data have implications for our understanding of ECM dynamics in stress-related diseases in which HSF1 is activated, and where the clinical application of N-terminal Hsp90 inhibitors is intended.
- Full Text:
- Authors: Dhanani, Karim C H , Samson, William J , Edkins, Adrienne L
- Date: 2017
- Language: English
- Type: article , text
- Identifier: http://hdl.handle.net/10962/59931 , vital:27711 , https://doi:10.1038/s41598-017-18061-y
- Description: Fibronectin is an extracellular matrix glycoprotein with key roles in cell adhesion and migration. Hsp90 binds directly to fibronectin and Hsp90 depletion regulates fibronectin matrix stability. Where inhibition of Hsp90 with a C-terminal inhibitor, novobiocin, reduced the fibronectin matrix, treatment with an N-terminal inhibitor, geldanamycin, increased fibronectin levels. Geldanamycin treatment induced a stress response and a strong dose and time dependent increase in fibronectin mRNA via activation of the fibronectin promoter. Three putative heat shock elements (HSEs) were identified in the fibronectin promoter. Loss of two of these HSEs reduced both basal and geldanamycin-induced promoter activity, as did inhibition of the stress-responsive transcription factor HSF1. Binding of HSF1 to one of the putative HSE was confirmed by ChIP under basal conditions, and occupancy shown to increase with geldanamycin treatment. These data support the hypothesis that fibronectin is stress-responsive and a functional HSF1 target gene. COLA42 and LAMB3 mRNA levels were also increased with geldanamycin indicating that regulation of extracellular matrix (ECM) genes by HSF1 may be a wider phenomenon. Taken together, these data have implications for our understanding of ECM dynamics in stress-related diseases in which HSF1 is activated, and where the clinical application of N-terminal Hsp90 inhibitors is intended.
- Full Text:
The palladacycle, AJ-5, exhibits anti-tumour and anti-cancer stem cell activity in breast cancer cells:
- Aliwaini, Saeb, Peres, Jade, Kröger, Wendy L, Blanckenberg, Angelique, de la Mare, Jo-Anne, Edkins, Adrienne L, Mapolie, Selwyn, Prince, Sharon
- Authors: Aliwaini, Saeb , Peres, Jade , Kröger, Wendy L , Blanckenberg, Angelique , de la Mare, Jo-Anne , Edkins, Adrienne L , Mapolie, Selwyn , Prince, Sharon
- Date: 2015
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/164874 , vital:41180 , DOI: 10.1016/j.canlet.2014.11.027
- Description: Breast cancer is the most common malignancy amongst women worldwide but despite enormous efforts to address this problem, there is still limited success with most of the current therapeutic strategies. The current study describes the anti-cancer activity of a binuclear palladacycle complex (AJ-5) in oestrogen receptor positive (MCF7) and oestrogen receptor negative (MDA-MB-231) breast cancer cells as well as human breast cancer stem cells. AJ-5 is shown to induce DNA double strand breaks leading to intrinsic and extrinsic apoptosis and autophagy cell death pathways which are mediated by the p38 MAP kinase. This study provides evidence that AJ-5 is potentially an effective compound in the treatment of breast cancer.
- Full Text:
- Authors: Aliwaini, Saeb , Peres, Jade , Kröger, Wendy L , Blanckenberg, Angelique , de la Mare, Jo-Anne , Edkins, Adrienne L , Mapolie, Selwyn , Prince, Sharon
- Date: 2015
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/164874 , vital:41180 , DOI: 10.1016/j.canlet.2014.11.027
- Description: Breast cancer is the most common malignancy amongst women worldwide but despite enormous efforts to address this problem, there is still limited success with most of the current therapeutic strategies. The current study describes the anti-cancer activity of a binuclear palladacycle complex (AJ-5) in oestrogen receptor positive (MCF7) and oestrogen receptor negative (MDA-MB-231) breast cancer cells as well as human breast cancer stem cells. AJ-5 is shown to induce DNA double strand breaks leading to intrinsic and extrinsic apoptosis and autophagy cell death pathways which are mediated by the p38 MAP kinase. This study provides evidence that AJ-5 is potentially an effective compound in the treatment of breast cancer.
- Full Text:
Breast cancer: current developments in molecular approaches to diagnosis and treatment
- de la Mare, Jo-Anne, Contu, Lara, Hunter, Morgan C, Moyo, Buhle, Sterrenberg, Jason N, Dhanani, Karim C H, Mutsvunguma, Lorraine Z, Edkins, Adrienne L
- Authors: de la Mare, Jo-Anne , Contu, Lara , Hunter, Morgan C , Moyo, Buhle , Sterrenberg, Jason N , Dhanani, Karim C H , Mutsvunguma, Lorraine Z , Edkins, Adrienne L
- Date: 2014
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/164819 , vital:41175 , DOI: 10.2174/15748928113086660046
- Description: Due to the high heterogeneity of breast cancers, numerous recent patents describe improved methods of detection and classification which promise better patient prognosis and treatment. In particular, there has been a shift towards more effective genetic screening to identify specific mutations associated with breast tumours, which may lead to “personalised medicine” with improved outcomes. Two challenging areas of breast cancer research involve the development of treatments for the highly aggressive triple negative breast cancer subtype as well as the chemotherapy-resistant cancer stem cell subpopulation. In addition, despite numerous recent advances in breast cancer treatment in woman, male breast cancer remains poorly understood and there are limited therapies available which are developed specifically for men. This review serves to report on important developments in the treatment of breast malignancies patented in the past two years as well as to highlight the current gaps in the field of breast cancer therapeutics and areas which require further study.
- Full Text:
- Authors: de la Mare, Jo-Anne , Contu, Lara , Hunter, Morgan C , Moyo, Buhle , Sterrenberg, Jason N , Dhanani, Karim C H , Mutsvunguma, Lorraine Z , Edkins, Adrienne L
- Date: 2014
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/164819 , vital:41175 , DOI: 10.2174/15748928113086660046
- Description: Due to the high heterogeneity of breast cancers, numerous recent patents describe improved methods of detection and classification which promise better patient prognosis and treatment. In particular, there has been a shift towards more effective genetic screening to identify specific mutations associated with breast tumours, which may lead to “personalised medicine” with improved outcomes. Two challenging areas of breast cancer research involve the development of treatments for the highly aggressive triple negative breast cancer subtype as well as the chemotherapy-resistant cancer stem cell subpopulation. In addition, despite numerous recent advances in breast cancer treatment in woman, male breast cancer remains poorly understood and there are limited therapies available which are developed specifically for men. This review serves to report on important developments in the treatment of breast malignancies patented in the past two years as well as to highlight the current gaps in the field of breast cancer therapeutics and areas which require further study.
- Full Text:
Cytotoxicity of lapachol, β-lapachone and related synthetic 1, 4-naphthoquinones against oesophageal cancer cells:
- Sunassee, Suthananda N, Veale, Clinton G L, Shunmoogam-Gounden, Nelusha, Osoniyi, Omalaja, Hendricks, Denver T, Caira, Mino R, De la Mare, Jo-Anne, Edkins, Adrienne L, Pinto, Antônio V, Da Silva Junior, Eufrânio N, Davies-Coleman, Michael T
- Authors: Sunassee, Suthananda N , Veale, Clinton G L , Shunmoogam-Gounden, Nelusha , Osoniyi, Omalaja , Hendricks, Denver T , Caira, Mino R , De la Mare, Jo-Anne , Edkins, Adrienne L , Pinto, Antônio V , Da Silva Junior, Eufrânio N , Davies-Coleman, Michael T
- Date: 2013
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/165207 , vital:41218 , DOI: 10.1016/j.ejmech.2012.12.048
- Description: Naphthoquinones have been found to have a wide range of biological activities, including cytotoxicity to cancer cells. The secondary metabolites lapachol, α- and β-lapachone and a series of 25 related synthetic 1,4-naphthoquinones were screened against the oesophageal cancer cell line (WHCO1). Most of the compounds exhibited enhanced cytotoxicity (IC50 1.6–11.7 μM) compared to the current drug of choice cisplatin (IC50 = 16.5 μM).
- Full Text:
- Authors: Sunassee, Suthananda N , Veale, Clinton G L , Shunmoogam-Gounden, Nelusha , Osoniyi, Omalaja , Hendricks, Denver T , Caira, Mino R , De la Mare, Jo-Anne , Edkins, Adrienne L , Pinto, Antônio V , Da Silva Junior, Eufrânio N , Davies-Coleman, Michael T
- Date: 2013
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/165207 , vital:41218 , DOI: 10.1016/j.ejmech.2012.12.048
- Description: Naphthoquinones have been found to have a wide range of biological activities, including cytotoxicity to cancer cells. The secondary metabolites lapachol, α- and β-lapachone and a series of 25 related synthetic 1,4-naphthoquinones were screened against the oesophageal cancer cell line (WHCO1). Most of the compounds exhibited enhanced cytotoxicity (IC50 1.6–11.7 μM) compared to the current drug of choice cisplatin (IC50 = 16.5 μM).
- Full Text:
- «
- ‹
- 1
- ›
- »